Global market size is about 35.6 billion U.S. dollars，and it will continue to grow; domestic market import products account for most shares，Domestic brands strive to fight for。

 

  Insulin is an irreplaceable product for the treatment of diabetes，Insulin products include: human insulin and analogs (Human Insulins and Analogues)、Animal Insulins、Insulin Devices。

 

  Global

 

  According to statistics，12 months as of March 2016 (April 2015 to March 2016，The same below)，Global insulin products are about 35.6 billion US dollars，52%of the diabetes drug market (US $ 35.6 billion/$ 68.3 billion)。Global human insulin and analgesic preparations are about $ 35.3 billion (99.3%of the insulin market)，Press the floating exchange rate、Fixed exchange rate meter (the same below)，increased by 11%respectively、15%。Animal insulin is about $ 26 million (0.1%of the insulin market)，increased by 3%respectively、8%。Insulin equipment is about $ 200 million (0.6%of the insulin market)，increased -6%respectively、4%。This article mainly analyzes human insulin and analog market。

 

  Four regional human insulin and analog market performance in the world see Figure 1。

 

 

  China is second

 

  According to statistics，12 months as of March 2016，The size of the American insulin and analogy market size is about 26 billion U.S. dollars，accounting for 74%of the global market (US $ 26 billion/$ 35.3 billion)，It is the world's largest human insulin and analog of the country market，increased by 18%year -on -year，It is the country with the highest growth rate in the world's mainstream pharmaceutical market。my country is the world's second major insulin Stake Sports Bettingand Stake Sports Bettinganalogy market，The market size is about 1.24 billion US dollars，The year -on -year increase was 6%、9%。

 

 The top three are dominated by the global market

 

  Nondor Nord is the world's leading insulin and analogy company，annual sales of about $ 13.7 billion，The top of the world's leading insulin and analog sales companies，See Figure 2。

 

 

  From Figure 2 to know，The world's leading 4 family insulin and analog company CR4 = 97.7%& Ge; 85%，Therefore, its market structure is oligopoly。Facts，Novo and Nord、Sanofi and Lilly dominated the global human insulin and analog market。

 

  Domestic

 

  Imported products account for about 9 % share

 

  According to the PDB data of the China Pharmaceutical Industry Information Center，2005 to the 1st quarter of 2016，Insulin therapy for small category domestic 22 city sample hospital procurement amount trend, see Figure 3。

 

 

  2005-2015 compound annual growth rate was 19.5%，Near 2、Three -year growth rate slowed，growth rate is less than 10%。

 

  According to PDB data，In 2015, 7 varieties entered 22 city sample hospital purchases，that is: glycone insulin、Door Winter insulin、Symistic protein -zinc insulin、Remaining Cascane、Insulin、Di special insulin、Lai Gulin insulin，It belongs to 9 companies。(see Figure 4)

 

 

  Gambing insulin residence

 

  According to PDB data，2015 Ganjin Precision Insulin Domestic Sample Hospital's purchase amount is nearly 500 million yuan，The first of the small category of insulin therapy。Where，Sanofer's product medication amount is nearly 400 million yuan，80%; Tonghua Dongbao Group Beijing Ganli Pharmaceutical Co., Ltd.'s product medication amount is 100 million yuan，accounting for 20%。2005-2015 Gan Jing insulin to the domestic sample hospital to compound annual growth rate of 59%(see Figure 5)，The highest sales among small varieties in insulin therapy、The fastest development of the market。

 

 

  variety

 

  1. Gambing insulin

 

  New dosage form brings a small surprise

 

  Gambing insulin was created by Sanofi, France，For long -term reorganization of insulin analogs，Use 1 time in 24 hours，For type 1、Type 2 Diabetes，2000 in Germany、Sweden first listing，Listed in the United States in 2001，Now in Europe、Japan and other major pharmaceutical markets are listed，Commodity name: Lantus。2015 global glycry insulin sales of $ 11.45 billion (of which Sanofi's Lantus sales of 7.09 billion US dollars，accounting for 62%)，It is estimated that Lantus sales will reach 3.38 billion US dollars in 2021。

 

  In our country，Gambing insulin injection imported drug products are called stake sports betting apptime stake betting apptime，The main specifications are: 10ml: 1000 units/support、3ml: 300 units/pens/pre -filled (soloStar)。Chinese products are reorganized glycamon insulin injection，The product is named Changxiulin，The main specifications are 10ml: 1000 units/bottle。

 

  Sanofi Company has developed glycry insulin implants，It is flatter than the injection of glycry glycry insulin、longer pharmaceutical dynamics、Pharmacy characteristics。Gambling insulin implantation is now in the United States (March 2015)、UK、Germany (July 2015)、The Netherlands (July 2015) launched，Commodity name: Toujeo，In Japan (product name: Lantus XR) and Australia have been approved。2015 Saiffei's glycry insulin implant sales of glyphosate reached 182 million US dollars，It is estimated that sales in 2021 will reach 1.884 billion US dollars。

 

  Gambing insulin Lesica is new to the market

 

  The fixed dose compound preparation of glycry insulin and Lixisenatide was created by Zealand Pharmaceutical Company，license to Sanofi Company。

 

  Licilal is a glucagon-likepeptide1，GLP-1) receptor agonist。March 2013，Lisila is listed in the Britain and Scandinavia，Listed in EU countries since then，The United States approved Lisila in July 2016 to assist patients with diet and exercise for adult type 2 diabetes。

 

  Gambing insulin Lesici Laipai compound preparation can be used for treatment type 1、Type 2 Diabetes。On May 25, 2015, the US FDA suggested to approve glycry insulin insulin Lesica to compound preparation for type 2 diabetes; in Europe，This compound preparation is also being approved for type 2 diabetes。Gambing insulin Lesica Laipai compound preparation for the clinical trial of type 1 diabetes is undergoing。

 

  2. Doom Winter insulin

 

  Insulin Aspart (Insulin Aspart) was created by Dannino and Nord，This product is fast -acting、Short -acting reorganized human insulin category，Injection immediately before meals，Quickly effective、Short action time，For type 1、Type 2 Diabetes。September 1999 in Switzerland、Britain and Germany for the first time，Later in many countries around the world，Including North America、South America、Japan and other countries in Europe，Product name NOVORAPID。

 

  In our country，The imported drug product name Nuo He Rui，The main specifications are 3ml: 300 units。domestic Nuo and Nord (China) Pharmaceutical Co., Ltd.，Main specifications 100 units/ml，3 ml/support (pen core)、3ml: 300 unit (pen core)。2015 Novorapid'stake betting apps global Stake Sports Bettingsales of Novorapid，It is estimated that sales in 2021 will reach $ 4.8 billion。

 

  3. Remaining insulin

 

  INSULIN LISPRO is re -re -given insulin，Created by Lilly Company in the United States，Permit to India's Sun Company。Lilly Company first in Switzerland in February 1996、Russia、South Africa is used for preserved cagiopa for the treatment of diabetes，Since then, it has been widely launched in Europe and the United States，Product name Humalog。

 

  my country approves imported drugs to be hybrid injections for seminal zinc reorganization.，Commodity name is You Bolle，Main specifications: 3ml: 300 units (pre -installed injection pen)、3ml: 300 unit (pen core)。Approval of domestic drugs as a seminal zinc reorganization and a preserved insulin hybrid injection (May 2014)，Main specifications: 3ml: 300 units; reorganization of insulin injection (November 2015)，Main specifications: 3ml: 300 units/branches (pens)。

 

  2015 Lai Lai's preserved insulin global sales are US $ 2.84 billion，It is estimated that sales in 2021 will reach US $ 2.7 billion。

 

  4. Di special insulin

 

  2015 global sales of 165 million US dollars

 

  Disulin Degludec is an ultra -long -effect insulin category，Created by Dantino and Nordon Company，injection administration，Listed in the UK for the first time in March 2013，Once once a day for treatment type 1、Type 2 Diabetes，Product name Tresiba，Subsequent product in the United States、Japan、Europe and other countries are listed。2015 Nuo and Nord's Global Special Insulin Global Sales $ 165 million，It is estimated that sales in 2021 will reach $ 4.1 billion。

 

  Di Sterture Sulira Twide Peptide was launched last year

 

  Di special insulin and liraglutide fixed dose compound preparations created by Nuo and Nord，The first time to be listed in Switzerland in January 2015，In the United Kingdom in August of the same year、Board of Germany。

 

  For a single use of an oral hypoglycemic drug or a basic insulin or a GLP-1 agonist, patients with type 2 diabetes who cannot obtain appropriate blood glucose control，European -approved Diqi Incardine Suliratan Peptide compound preparation and oral hypoglycemic drugs to improve blood glucose control of this type of diabetes。In September 2015, Novo and Noord submitted to the US FDA the new drug listing of Di special insulcotin compound preparations，In May 2016, the US FDA Consulting Committee all agreed to the proposal for approval。

 

  2015 Nuo and Nord's Earth Special Incarnation Sulelalugin compound preparation sales of 36 million US dollars，It is estimated that sales in 2021 will reach $ 1.7 billion。

 

  Conclusion & lt; & lt; & lt;

 

  Based on the above market stake online sports bettingstake sports betting appdata, you can see，Global human insulin and analog products are large market medications and continue to grow。There are 4 factors that drive this market: First, the target group of medication is increasing; the other is that human insulin and analogy can be used in patients with type 1 diabetes，It can also be used for patients with type 2 diabetes，Especially due to the increase in the number of obesity in the world，Type 2 diabetes medication market has developed rapidly; third is long -acting insulin、High -concentration insulin preparations and fixed dosage compound preparations are launched in the market; fourth is the advent of similar drugs in the leading products (especially when it comes)。

 

  my country's insulin variety market has grown rapidly in ten years，But near 2、Three -year growth rate slowed。Currently imported human insulin and similar substances occupy most of the market share，But domestic product species are fighting for competition，Market share gradually increases。